• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤内激活 41BB 共刺激信号增强 CD8 T 细胞扩增并调节肿瘤浸润髓样细胞。

Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells.

机构信息

Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612.

Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL 33620; and.

出版信息

J Immunol. 2020 Nov 15;205(10):2893-2904. doi: 10.4049/jimmunol.2000759. Epub 2020 Oct 5.

DOI:10.4049/jimmunol.2000759
PMID:33020146
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7741883/
Abstract

The activation of 41BB costimulatory signals by agonistic Abs enhances the expansion and function of tumor-infiltrating lymphocytes (TILs) for treating cancer patients with adoptive cell therapy. However, the impact of 41BB agonism is not limited to enhancing the activity of T cells, and the mechanism by which additional activation of this costimulatory axis in tumor-associated myeloid cells is poorly understood. In this study, we describe that the intratumoral administration of 41BB agonistic Abs led to increases in CD8 T cell infiltration followed by tumor regression in murine models. We found that granulocytes and monocytes rapidly replaced macrophages and dendritic cells in tumors following administration of anti-41BB Abs. Overall, myeloid cells from anti-41BB-treated tumors had an improved capacity to stimulate T cells in comparison with control-treated tumors. In human coculture systems, we demonstrated that the agonism of the 41BB-41BBL axis enhanced costimulatory signals and effector functions among APC and autologous TILs. Overall, these findings suggest that the effect of 41BB agonistic Abs are supported by additional costimulatory signals from tumor-associated myeloid cells,v leading to enhanced TIL expansion and function.

摘要

激动性抗体激活 41BB 共刺激信号可增强肿瘤浸润淋巴细胞(TIL)的扩增和功能,从而用过继细胞疗法治疗癌症患者。然而,41BB 激动作用的影响不仅限于增强 T 细胞的活性,并且在肿瘤相关髓样细胞中这条共刺激轴的额外激活的机制尚未完全阐明。在这项研究中,我们描述了在肿瘤内给予 41BB 激动性抗体可导致 CD8 T 细胞浸润增加,随后在小鼠模型中肿瘤消退。我们发现,在用抗 41BB 抗体治疗后,粒细胞和单核细胞迅速取代了肿瘤中的巨噬细胞和树突状细胞。总体而言,与对照治疗的肿瘤相比,来自抗 41BB 治疗的肿瘤的髓样细胞具有增强的刺激 T 细胞的能力。在人类共培养系统中,我们证明了 41BB-41BBL 轴的激动作用增强了 APC 和自体 TIL 之间的共刺激信号和效应功能。总体而言,这些发现表明,41BB 激动性抗体的作用得到了来自肿瘤相关髓样细胞的其他共刺激信号的支持,从而增强了 TIL 的扩增和功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/437d97e2050f/nihms-1628609-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/d0c5db59d10c/nihms-1628609-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/f5f15e194ade/nihms-1628609-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/e1692ae378af/nihms-1628609-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/b5a5d137b88d/nihms-1628609-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/7fba626c83db/nihms-1628609-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/6210a02e7a38/nihms-1628609-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/437d97e2050f/nihms-1628609-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/d0c5db59d10c/nihms-1628609-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/f5f15e194ade/nihms-1628609-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/e1692ae378af/nihms-1628609-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/b5a5d137b88d/nihms-1628609-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/7fba626c83db/nihms-1628609-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/6210a02e7a38/nihms-1628609-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8820/7741883/437d97e2050f/nihms-1628609-f0007.jpg

相似文献

1
Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells.肿瘤内激活 41BB 共刺激信号增强 CD8 T 细胞扩增并调节肿瘤浸润髓样细胞。
J Immunol. 2020 Nov 15;205(10):2893-2904. doi: 10.4049/jimmunol.2000759. Epub 2020 Oct 5.
2
Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.4-1BB/CD137 共刺激可改善过继性 T 细胞治疗中 CD8(+)黑色素瘤肿瘤浸润淋巴细胞的扩增和功能。
PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.
3
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.CD137/4-1BB 通路共刺激可保护人黑色素瘤肿瘤浸润淋巴细胞免于激活诱导的细胞死亡,并增强抗肿瘤效应功能。
J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec.
4
4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8 T Cells in Hepatocellular Carcinoma.4-1BB 描绘了肝癌中耗尽的肿瘤浸润 CD8 T 细胞的不同激活状态。
Hepatology. 2020 Mar;71(3):955-971. doi: 10.1002/hep.30881. Epub 2019 Oct 18.
5
4-1BB Agonist Focuses CD8 Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.4-1BB 激动剂将 CD8 肿瘤浸润性 T 细胞的生长集中到一个能够识别胰腺癌的独特 repertoire 中。
Clin Cancer Res. 2017 Dec 1;23(23):7263-7275. doi: 10.1158/1078-0432.CCR-17-0831. Epub 2017 Sep 25.
6
4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.4-1BB激动剂与PD-L1阻断联合使用可增加组织驻留CD8 + T细胞数量并促进肿瘤消除。
Front Immunol. 2020 Apr 24;11:577. doi: 10.3389/fimmu.2020.00577. eCollection 2020.
7
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.4-1BB 共刺激受体抗体通过耗竭调节性 T 细胞和促进 CD8+T 细胞效应功能增强抗肿瘤免疫。
Immunity. 2018 Nov 20;49(5):958-970.e7. doi: 10.1016/j.immuni.2018.09.014. Epub 2018 Nov 13.
8
The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications.影响膀胱癌反应性肿瘤浸润淋巴细胞(TIL)扩增的因素及潜在治疗应用。
Front Immunol. 2021 Feb 25;12:628063. doi: 10.3389/fimmu.2021.628063. eCollection 2021.
9
4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.4-1BB配体介导的人T细胞共刺激可诱导CD4和CD8 T细胞扩增、细胞因子产生以及细胞溶解效应功能的发展。
J Immunol. 2002 May 15;168(10):4897-906. doi: 10.4049/jimmunol.168.10.4897.
10
4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.4-1BB 激动剂可避免 TIL 耗竭并在胶质母细胞瘤和其他颅内癌中许可 PD-1 阻断。
Clin Cancer Res. 2020 Mar 15;26(6):1349-1358. doi: 10.1158/1078-0432.CCR-19-1068. Epub 2019 Dec 23.

引用本文的文献

1
Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy.通过瘤内免疫疗法对肿瘤-淋巴管串扰进行治疗性免疫调节
Mol Pharm. 2024 Dec 2;21(12):5929-5943. doi: 10.1021/acs.molpharmaceut.4c00692. Epub 2024 Oct 31.
2
Recent clinical researches and technological development in TIL therapy.TIL 疗法的最新临床研究和技术进展。
Cancer Immunol Immunother. 2024 Sep 12;73(11):232. doi: 10.1007/s00262-024-03793-4.
3
modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes.

本文引用的文献

1
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8 T Cells.肿瘤内过继转移 IL-12 mRNA 瞬时修饰抗肿瘤 CD8 T 细胞。
Cancer Cell. 2019 Dec 9;36(6):613-629.e7. doi: 10.1016/j.ccell.2019.10.006. Epub 2019 Nov 21.
2
CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives.CD137L-DCs,高效免疫刺激剂——历史、特征和展望。
Front Immunol. 2019 Oct 2;10:2216. doi: 10.3389/fimmu.2019.02216. eCollection 2019.
3
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
用抗 PD-1 和抗 CTLA-4 对完整肿瘤片段进行调制,影响肿瘤浸润淋巴细胞的扩增和特异性。
Front Immunol. 2023 Jun 8;14:1180997. doi: 10.3389/fimmu.2023.1180997. eCollection 2023.
4
Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities.肿瘤相关巨噬细胞的动态极化及其在炎症肿瘤微环境中与肿瘤内 T 细胞的相互作用:从机制见解到治疗机会。
Front Immunol. 2023 May 12;14:1160340. doi: 10.3389/fimmu.2023.1160340. eCollection 2023.
5
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy.针对 TNF 超家族共刺激受体的癌症免疫疗法。
BioDrugs. 2023 Jan;37(1):21-33. doi: 10.1007/s40259-022-00573-3. Epub 2022 Dec 26.
6
Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.抗 4-1BB 免疫疗法增强了放疗的全身免疫效应,诱导 B 和 T 细胞依赖的抗肿瘤免疫激活,并改善了未照射部位的肿瘤控制。
Cancer Immunol Immunother. 2023 Jun;72(6):1445-1460. doi: 10.1007/s00262-022-03325-y. Epub 2022 Dec 5.
7
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.纳武利尤单抗联合 CD137 激动剂和肿瘤浸润淋巴细胞过继细胞疗法治疗转移性黑色素瘤患者。
Clin Cancer Res. 2022 Dec 15;28(24):5317-5329. doi: 10.1158/1078-0432.CCR-22-2103.
8
Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine.通过携带共刺激TNFSF配体和GM-CSF细胞因子的PSMA靶向免疫调节病毒样颗粒增强抗肿瘤反应。
Mol Ther Oncolytics. 2022 Feb 17;24:650-662. doi: 10.1016/j.omto.2022.02.010. eCollection 2022 Mar 17.
9
Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors.瘤内注射孟加拉玫瑰红增强吉西他滨化疗治疗胰腺肿瘤的疗效。
BMC Cancer. 2021 Jun 30;21(1):756. doi: 10.1186/s12885-021-08522-z.
肿瘤靶向 4-1BB 激动剂与 T 细胞双特异性抗体联合作为现货治疗。
Sci Transl Med. 2019 Jun 12;11(496). doi: 10.1126/scitranslmed.aav5989.
4
Twists and turns to translating 4-1BB cancer immunotherapy.4-1BB 癌症免疫疗法的曲折历程。
Sci Transl Med. 2019 Jun 12;11(496). doi: 10.1126/scitranslmed.aax4738.
5
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.组成型和诱导型趋化因子的合作使 T 细胞在实体瘤中植入和免疫攻击成为可能。
Cancer Cell. 2019 Jun 10;35(6):885-900.e10. doi: 10.1016/j.ccell.2019.05.004.
6
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.一种肿瘤靶向的三聚体 4-1BB 激动性抗体,可诱导强烈的抗肿瘤免疫而无全身毒性。
Nat Commun. 2018 Nov 15;9(1):4809. doi: 10.1038/s41467-018-07195-w.
7
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.4-1BB/4-1BBL 复合物的结构以及utomilumab 和 urelumab 的独特结合和功能特性。
Nat Commun. 2018 Nov 8;9(1):4679. doi: 10.1038/s41467-018-07136-7.
8
Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab.4-1BB 配体和激动型单克隆抗体 Utomilumab 对 4-1BB 的有限交联。
Cell Rep. 2018 Oct 23;25(4):909-920.e4. doi: 10.1016/j.celrep.2018.09.073.
9
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.伊匹单抗与肿瘤浸润淋巴细胞过继性细胞疗法联合用于转移性黑色素瘤患者的治疗
Front Oncol. 2018 Mar 2;8:44. doi: 10.3389/fonc.2018.00044. eCollection 2018.
10
Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.抗 CD137 通过阻断 CD137 配体的反向信号抑制肿瘤生长。
Cancer Res. 2017 Nov 1;77(21):5989-6000. doi: 10.1158/0008-5472.CAN-17-0610. Epub 2017 Sep 18.